What's in Changchun GeneScience Pharmaceutical Co., Ltd.'s pipeline?

Changchun GeneScience Pharmaceutical Co., Ltd. has 45 drugs in our index: 3 marketed, 0 filed, 12 in Phase 3, 13 in Phase 2, 17 in Phase 1.

Which companies overlap with Changchun GeneScience Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Qilu Pharmaceutical Co., Ltd., Bayer, JW Pharmaceutical, Merck KGaA, Darmstadt, Germany, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/changchun-genescience-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Changchun GeneScience Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Changchun GeneScience Pharmaceutical Co., Ltd. pipeline: 3 marketed, 0 filed, 12 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 12 Phase 3 13 Phase 2 17 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
PEG-somatropin	PEG-somatropin	marketed	Growth hormone receptor agonist	Growth hormone receptor (GHR)	Endocrinology
rhGH injection	rhGH injection	marketed	Growth hormone	Growth hormone receptor (GHR)	Endocrinology
Diprospan	Diprospan	marketed			Other
Bromocriptine mesylate tablets	Bromocriptine mesylate tablets	phase 3	Dopamine D2 receptor agonist	Dopamine D2 receptor	Endocrinology
Triptorelin for Injection	Triptorelin for Injection	phase 3	GnRH agonist	GnRH receptor	Oncology
GenSci004	GenSci004	phase 3	Growth hormone analog	Growth hormone receptor	Endocrinology
GenSci094	GenSci094	phase 3	Growth hormone analog	Growth hormone receptor	Endocrinology
genakumab	genakumab	phase 3			Other
Placebo RecFSH / follitropin alfa	Placebo RecFSH / follitropin alfa	phase 3	Gonadotropin; recombinant FSH	FSH receptor (FSHR)	Reproductive/Fertility
Leuprorelin Acetate Microspheres for Injection	Leuprorelin Acetate Microspheres for Injection	phase 3	GnRH agonist	GnRH receptor	Oncology; Endocrinology
Progesterone Soft Capsules	Progesterone Soft Capsules	phase 3	Progestogen	Progesterone receptor	Gynecology
Gentuximab Injection	Gentuximab Injection	phase 3	VEGF inhibitor monoclonal antibody	VEGF (Vascular Endothelial Growth Factor)	Oncology

Therapeutic area mix

Endocrinology · 6
Oncology · 2
Oncology; Endocrinology · 2
Other · 2
Dermatology · 1
Reproductive/Fertility · 1
Diabetes · 1
Gynecology · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
Bayer · 2 shared drug classes
JW Pharmaceutical · 2 shared drug classes
Merck KGaA, Darmstadt, Germany · 2 shared drug classes
Takeda · 2 shared drug classes
Abbott · 2 shared drug classes
AbbVie (prior sponsor, Abbott) · 1 shared drug class
AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Changchun GeneScience Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Changchun GeneScience Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/changchun-genescience-pharmaceutical-co-ltd. Accessed 2026-05-17.